Results 151 to 160 of about 74,045 (223)

Early expression of chromogranin A and tyrosine hydoxylase during prenatal development of the bovine adrenal gland [PDF]

, 1994
Amselgruber, W., Gratzl, Manfred, Sinowatz, F., Totzauer, I.   +3 more
core   +1 more source

Dopaminergic Innervation of the Nidopallium Caudolaterale in the Japanese Quail

Journal of Comparative Neurology, Volume 534, Issue 4, April 2026.
The nidopallium caudolaterale (NCL) of the Japanese quail was delineated based on quantitative TH+ fiber density, identifying it as the primary dopaminergic target within the pallium. TH+ basket‐like structures predominantly surrounded CaMKIIa+ excitatory neurons, with sparse contacts onto GABAergic interneurons.
Defne Albayrak, Sinem Gencturk, Kevin B. Haselhuhn, Cem Sevinc, Onur Güntürkün, Mehdi Behroozi, Noemi Rook, Gunes Unal   +7 more
wiley   +1 more source

Adrenergic receptor activation triggers stress-induced dystonia in a CACNA1A mutant mouse model. [PDF]

Front Neurosci
Bohne P, Grömmke M, Rybarski M, Nair T, Mark MD.   +4 more
europepmc   +1 more source

Nps‐Expressing Neurons Receive Extensive Input From Auditory Brainstem Nuclei

Journal of Comparative Neurology, Volume 534, Issue 4, April 2026.
Nps‐expressing neurons receive input from auditory brainstem nuclei, with additional afferents from the reticular formation, midbrain, hypothalamus, and extended amygdala. While rabies retrograde labeling in the cerebral cortex was sparse, cholera toxin beta (CTb) revealed copious input, and anterograde tracing identified many axons and boutons ...
Richie Zhang, Silvia Gasparini, Joel C. Geerling   +2 more
wiley   +1 more source

Synergetic effect of a DSP4-induced locus coeruleus lesion and systemic LPS exacerbates substantia nigra dopaminergic neuron loss. [PDF]

Sci Rep
Şimşek F, Papová D, Henriksson E, Olmedo-Díaz S, Blyberg M, El-Habta R, Virel A, Af Bjerkén S.   +7 more
europepmc   +1 more source

The Viloxazine Paradox: A Noradrenergic Agent's Journey From Antidepressant Obscurity to ADHD Precision Therapy

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
Viloxazine, a serotonin–norepinephrine modulating agent, has been repurposed from an antidepressant to a novel non‐stimulant for ADHD. Its multimodal mechanism and Phase II/III trials demonstrate clinically meaningful symptom reduction with a distinct safety and interaction profile, offering an alternative for patients who cannot tolerate stimulants ...
Ghaith K. Mansour, Sabry Babiker H. Sayed, Sajjad Ghanim Al‐Badri, Mohammed Gamaleldin Abdulrahim Abdalla, Dina Essam Abo‐elnour   +4 more
wiley   +1 more source

Predicting Long‐Term Depression Progression in Parkinson's Disease: A Machine‐Learning Survival Analysis and Risk Score

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
We developed and internally validated a machine learning–based survival model for predicting long‐term progression of dPD. Supported by SHAP analysis, the model identified that depressive symptom severity, cognitive impairment, and autonomic dysfunction were the main key clinical predictors for dPD progression.
Defu Liu, Chong Qi, Jiansong Huang, Hutao Xie, Yutong Zhuang, Quan Zhang, Xuemin Zhao, Tianqi Hu, Guofan Qin, Yue Lu, Xin Zhang, Sizhe Li, Mingyu Yang, Jianguo Zhang, Yin Jiang   +14 more
wiley   +1 more source

The potential of neuromelanin-sensitive MRI in psychiatric disorders. [PDF]

Neurosci Appl
Neutelings E, van de Giessen E, de Haan L, van der Pluijm M.   +3 more
europepmc   +1 more source

Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial

Clinical Pharmacology in Drug Development, Volume 15, Issue 4, April 2026.
Abstract This single‐center, open‐label, randomized, multiple‐dose, pharmacokinetic bridging study was conducted to compare systemic exposure (AUC and Cmax) of a sublingual tablet formulation of cyclobenzaprine hydrochloride (TNX‐102 SL, approved as TONMYA) at steady‐state with that of an approved reference product, an oral, extended‐release (ER ...
Gregory M. Sullivan, Bernd Meibohm, Errol Gould, Bruce L. Daugherty, Seth Lederman   +4 more
wiley   +1 more source

Symptomatic Pheochromocytoma: A Risk Model. [PDF]

Cancers (Basel)
Muñoz MC, Febrero B, Abellán M, Rodríguez JM.   +3 more
europepmc   +1 more source